Novo Nordisk’s next-gen weight loss drug outperforms Zepbound in new trial

AI Summary

Novo Nordisk says its investigational next-generation weight-loss drug produced greater weight loss than Zepbound in a major clinical trial. The findings position the candidate as a potential successor to Wegovy, though the article provides no further trial details.

Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.